Delving into the Latest Updates on Astragalus polysaccharide with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

ASPS

Target

PDL1

Action

inhibitors, stimulants

Mechanism

PDL1 inhibitors(Programmed death-ligand 1 inhibitors), Apoptosis inhibitors, Stem cells stimulants

Therapeutic Areas

NeoplasmsInfectious DiseasesNervous System Diseases+ [4]

Active Indication

Bladder CancerCognition DisordersEncephalomyelitis+ [2]

Inactive Indication-

Originator Organization

Sun Yat-Sen University

Active Organization

Affiliated Hospital of Guangdong Medical University

Shanghai University of Traditional Chinese Medicine

Sun Yat-Sen University

+ [1]

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

To investigate the effect of astragalus polysaccharide (APS) in the treatment of ulcerative colitis (UC) and its molecular mechanisms, particularly through the ability to regulate Treg cell-glycolytic interactions. BALB/c mice were used to establish DSS-induced UC model, and administered with APS (200 mg/kg) as a therapeutic intervention. During the study, flow cytometry was employed to analyze the changes in the proportions of Treg cells and their related subpopulations in the spleens of mice. Additionally, the expression levels of various cytokines in the colon tissues were detected simultaneously. To further investigate the mechanism of action of APS, RNA sequencing was also performed on the colon tissues, and the regulatory effects of APS on glycolysis and mTOR/HIF-1α signaling pathway were revealed by KEGG pathway analysis, western blot, RT-qPCR and other techniques. In this study, we found that APS not only substantially ameliorated the adverse symptoms in UC mice, but also promoted the expression of anti-inflammatory cytokines and suppressed the levels of pro-inflammatory cytokines by regulating the distribution of Treg cells and their subpopulations. Furthermore, the molecular mechanism by which APS exerts its protective effects by inhibiting glycolysis and mTOR/HIF-1α signaling pathway was revealed through RNA sequencing, KEGG pathway analysis, and other techniques. The study revealed that APS effectively ameliorated the symptoms of UC in mice by regulating Treg cells, inhibiting glycolysis and mTOR/HIF-1α signaling pathway, providing a scientific basis and potential therapeutic target for the application of APS in UC treatment.

14 Jul 2025·ACS Biomaterials Science & Engineering

Correction to “Purified Astragalus Polysaccharide Combined with Inactivated Vaccine Markedly Prevents Infectious Haematopoietic Necrosis Virus Infection in Rainbow Trout (Oncorhynchus mykiss)”

Author: Quan, Jinqiang ; Wang, Jianfu ; Lu, Junhao ; Gu, Wei ; Wang, Junwei ; Zhao, Guiyan ; Pan, Yucai ; Liu, Zhe

01 Jul 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Effect of Astragalus polysaccharide combined with cisplatin on exhaled volatile organic compounds as biomarkers for lung cancer and its anticancer mechanism

Article

Author: Feng, Weisheng ; Shi, Wenmin ; Zhang, Zhijuan ; Zhang, Huanqing ; Tang, Hanxiao

Cisplatin (DDP) is widely used to fight lung cancer, but there is a risk of immune damage. Astragalus polysaccharides (APS) is the main active component of Astragalus membranaceus Bunge. It has demonstrated anticancer properties across a range of cancer types as well as to be effective against cisplatin induced immune damage. However, its therapeutic mechanism has not been fully explored. This study aimed to explore the antitumor mechanisms of APS and elucidate the relationship between APS and volatile organic compounds (VOCs) in exhaled breath of Lewis lung cancer (LLC) mice. Gas chromatography-mass spectrometry (GC-MS) was utilized to analyze the exhaled VOCs in LLC mice. A specific group of VOCs was identified as potential biomarkers for monitoring tumor progression. Furthermore, the effects of combined treatment with APS and DDP on the concentration of exhaled VOCs in LLC mice was evaluated. Stoichiometric analysis revealed that the levels of 12 VOCs exhibited substantial recovery following APS treatment. And a high concentration of APS (400 mg/kg), when combined with DDP, exhibited enhanced antitumor efficacy. The metabolic pathways involved in the action of APS include 12 pathways. Our methodology elucidated both the effects and mechanisms of APS on lung cancer, as well as the pharmacological enhancement of cisplatin by APS. These findings facilitate real-time monitoring of lung cancer treatments and contribute to the future development of anticancer therapies.

1

News (Medical) associated with Astragalus polysaccharide

16 Sep 2024

·www.prnewswire.com

PhytoHealth Corporation announced a new clinical study results published at 2024 ESMO Congress: PG2 plus preoperative chemoradiotherapy improves survival in patients with locally advanced esophageal cancer

TAIPEI and BARCELONA, Spain, Sept. 16, 2024 /PRNewswire/ -- A groundbreaking study conducted by PhytoHealth Corporation, a leading provider of botanical medicine, has revealed that combining Astragalus Polysaccharides (PG2®Lyo. Injection) with standard concurrent chemoradiotherapy (CCRT) significantly improves survival rates for patients with advanced esophageal cancer. The study enrolled 38 patients with stage IIb to IIIb esophageal cancer. Participants were randomly assigned to receive either CCRT alone or CCRT combined with PG2, a proprietary extract of Astragalus membranaceus roots developed by PhytoHealth Corporation. Results showed that patients who received PG2 in addition to CCRT experienced significantly longer overall survival compared to those who received CCRT alone. Furthermore, the combination therapy resulted in a higher tumor objective response rate. The study also found that PG2 helped strengthen the immune system by modulating the tumor immune microenvironment (TIME) and enhancing the suppression of tumor growth. 'These findings offer a new hope for patients with esophageal cancer,'' said Dr. Wen-Chieh Huang, Chief of Division of Thoracic Surgery at Mackay Memorial Hospital, Taiwan and the Principal Investigator of the clinical trial for PG2, a drug for cancer-related fatigue (CRF) relief developed by PhytoHealth Corporation, Taiwan. "PG2 has the potential to become a valuable addition to the standard treatment regimen, and can achieve improved patient outcomes.'' The data will be presented as a poster at the prestigious 2024 ESMO Congress. [ESMO abstract link]. Dr. Huang noted that treatment options for esophageal cancer patients are relatively limited compared to those for other cancers. However, this study has shown that PG2 combination therapy can reduce inflammation markers in the blood, decrease the differentiation of macrophages towards the M2 type, and even help shrink tumors while improving survival rates. This represents a significant breakthrough in the treatment of esophageal cancer. Dr. Huang further added that esophageal cancer patients often face tremendous challenges during treatment, with many unable to complete their therapy. However, by incorporating CRF medication, most patients were able to regain their strength, complete the full courses of cancer treatment, and achieve the expected therapeutic effects. Esophageal cancer is a challenging disease with high recurrence rates and poor survival outcomes. PG2, previously established as a treatment for cancer-related fatigue (already approved by Taiwan Food and Drug Administration) has shown promise as a potential treatment enhancer. This latest discovery marks a significant advancement in the ongoing battle against this challenging cancer. About PhytoHealth Corporation PhytoHealth Corporation is a leader in the development and manufacturing of botanical medicine and natural health products based in Taiwan. With a focus on scientific research and innovation, PhytoHealth is committed to providing safe, effective, and high-quality products that support overall health and well-being. Contact: Alison [email protected] Logo - WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Result

100 Deals associated with Astragalus polysaccharide

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bladder Cancer	Preclinical	China	Affiliated Hospital of Guangdong Medical University	02 May 2025
Cognition Disorders	Preclinical	China	He Bei Zhong Yi Yao Da Xue	02 May 2025
Encephalomyelitis	Preclinical	China	Shanghai University of Traditional Chinese Medicine	01 Dec 2024
Melanoma	Preclinical	China	Shanghai University of Traditional Chinese Medicine	21 Aug 2024
Thrombosis	Preclinical	China	Sun Yat-Sen University	08 Jul 2019